{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT05198245",
            "orgStudyIdInfo": {
                "id": "BHV3000-403"
            },
            "secondaryIdInfos": [
                {
                    "id": "C4951006",
                    "type": "OTHER",
                    "domain": "Alias Study Number"
                }
            ],
            "organization": {
                "fullName": "Pfizer",
                "class": "INDUSTRY"
            },
            "briefTitle": "Study of Pregnancy Outcomes in Women Exposed to Rimegepant During Pregnancy",
            "officialTitle": "Retrospective Cohort Study of Pregnancy Outcomes in Women Exposed to Rimegepant During Pregnancy",
            "therapeuticArea": [
                "Neurology"
            ],
            "study": "study-of-pregnancy-outcomes-in-women-exposed-to-rimegepant-during-pregnancy"
        },
        "statusModule": {
            "statusVerifiedDate": "2024-06",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2021-12-15",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2028-04-17",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2028-04-17",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2021-12-15",
            "studyFirstSubmitQcDate": "2022-01-03",
            "studyFirstPostDateStruct": {
                "date": "2022-01-20",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2024-06-06",
            "lastUpdatePostDateStruct": {
                "date": "2024-06-07",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR"
            },
            "leadSponsor": {
                "name": "Pfizer",
                "class": "INDUSTRY"
            },
            "collaborators": [
                {
                    "name": "RTI Health Solutions",
                    "class": "OTHER"
                },
                {
                    "name": "Optum, Inc.",
                    "class": "INDUSTRY"
                }
            ]
        },
        "oversightModule": {
            "oversightHasDmc": false,
            "isFdaRegulatedDrug": false,
            "isFdaRegulatedDevice": false
        },
        "descriptionModule": {
            "briefSummary": "The purpose of the study is to evaluate the risk of pregnancy and infant outcomes among women with migraine exposed to rimegepant during pregnancy and in two rimegepant unexposed comparator groups."
        },
        "conditionsModule": {
            "conditions": [
                "Migraine"
            ],
            "keywords": [
                "Migraine",
                "Migraine Disorder",
                "Migraine Prevention",
                "Prevention of Migraine",
                "Pregnant",
                "Pregnancy",
                "Infant"
            ]
        },
        "designModule": {
            "studyType": "OBSERVATIONAL",
            "patientRegistry": false,
            "designInfo": {
                "observationalModel": "COHORT",
                "timePerspective": "RETROSPECTIVE"
            },
            "enrollmentInfo": {
                "count": 8082,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "Pregnancies in women with migraine and exposure to rimegepant",
                    "interventionNames": [
                        "Drug: Rimegepant"
                    ]
                },
                {
                    "label": "Pregnancies in women with migraine exposed to other medications",
                    "description": "Pregnancies in women with migraine exposed to other medications indicated for the treatment of migraine",
                    "interventionNames": [
                        "Drug: Various"
                    ]
                },
                {
                    "label": "Pregnancies in women without migraine",
                    "interventionNames": [
                        "Other: No intervention"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "DRUG",
                    "name": "Rimegepant",
                    "description": "Rimegepant 75mg",
                    "armGroupLabels": [
                        "Pregnancies in women with migraine and exposure to rimegepant"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "Various",
                    "description": "Various",
                    "armGroupLabels": [
                        "Pregnancies in women with migraine exposed to other medications"
                    ]
                },
                {
                    "type": "OTHER",
                    "name": "No intervention",
                    "description": "No intervention",
                    "armGroupLabels": [
                        "Pregnancies in women without migraine"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Major congenital malformations, spontaneous abortions, fetal deaths/stillbirths, small for gestational age births",
                    "timeFrame": "Annually beginning April 2022"
                }
            ],
            "secondaryOutcomes": [
                {
                    "measure": "Elective terminations",
                    "timeFrame": "Annually beginning April 2022"
                },
                {
                    "measure": "Preterm births",
                    "timeFrame": "Annually beginning April 2022"
                },
                {
                    "measure": "Pre-eclampsia/eclampsia",
                    "timeFrame": "Annually beginning April 2022"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria (All Pregnancies):\n\nAll pregnant women aged 16 to 49 years, inclusive, at the estimated LMP within the study observation period are eligible to enter in the study.\n\nExclusion Criteria (All Pregnancies):\n\n* Has insufficient information to estimate LMP\n* Has at least 1 pharmacy dispensing for ditans (i.e., lasmiditan) within a 5-half-life time window before the estimated LMP through whichever is first: end of pregnancy or end of the study period\n* Has at least 1 pharmacy dispensing for a CGRP receptor antagonist other than rimegepant (i.e., ubrogepant, atogepant, and zavegepant) within a 5-half-life time window before the estimated LMP through whichever is first: end of pregnancy or end of the study period\n* Has at least 1 pharmacy dispensing for CGRP monoclonal antibodies (i.e., erenumab, fremanezumab, eptinezumab, and galcanezumab) within a 5-half-life time window before the estimated LMP through whichever is first: end of pregnancy or end of the study period\n\nAdditional Eligibility Criteria (Rimegepant-Exposed Group):\n\n* Have a migraine diagnosis any time before the estimated LMP and through whichever is first: end of pregnancy or end of the study period\n* Have at least 1 pharmacy dispensing for rimegepant within the 30-day time window before the estimated LMP and through whichever is first: end of pregnancy or end of the study period\n* Have a recorded outcome of pregnancy within the study period\n* Had continuous enrollment in a health care plan with medical and pharmacy benefits during the 6-month period before the estimated LMP through a postpartum period of 42 days\n\nAdditional Inclusion Criteria (Primary Comparator Group):\n\n* Have a migraine diagnosis any time before the estimated LMP and through whichever is first: end of pregnancy or end of the study period\n* Have at least 1 pharmacy dispensing for a medication indicated for the treatment of migraine within the 30-day time window before the estimated LMP and ending with whichever is first: end of pregnancy or end of the study period.\n* Have a recorded outcome of pregnancy within the study period\n* Had continuous enrollment in a health care plan with medical and pharmacy benefits during the 6-month period before the estimated LMP through a postpartum period of 42 days\n\nAdditional Exclusion Criteria (Primary Comparator Group):\n\n\u2022 Have at least 1 pharmacy dispensing for rimegepant within the 30-day time window before the estimated LMP and through whichever is first: end of pregnancy or end of the study period\n\nAdditional Inclusion Criteria (Secondary Comparator Group):\n\n* Have no migraine diagnosis any time before the estimated LMP through whichever is first: end of pregnancy or end of the study period\n* Have a recorded outcome of pregnancy within the study period\n* Had continuous enrollment in a health care plan with medical and pharmacy benefits during the 6-month period before the estimated LMP through a postpartum period of 42 days\n\nAdditional Exclusion Criteria (Secondary Comparator Group):\n\n\u2022 Have at least 1 pharmacy dispensing for rimegepant within the 30-day time window before the estimated LMP through whichever is first: end of pregnancy or end of the study period",
            "healthyVolunteers": false,
            "sex": "FEMALE",
            "minimumAge": "16 Years",
            "maximumAge": "49 Years",
            "stdAges": [
                "CHILD",
                "ADULT"
            ],
            "studyPopulation": "Study population will consist of pregnant women (any age) as well as the infants (male and female) born to enrolled participants through age 1 year",
            "samplingMethod": "NON_PROBABILITY_SAMPLE"
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Pfizer Pfizer CT.gov Call Center",
                    "role": "CONTACT",
                    "phone": "1-800-718-1021",
                    "email": "ClinicalTrials.gov_Inquiries@pfizer.com"
                }
            ],
            "overallOfficials": [
                {
                    "name": "Pfizer CT.gov Call Center",
                    "affiliation": "Pfizer",
                    "role": "STUDY_DIRECTOR"
                }
            ],
            "locations": [
                {
                    "facility": "Research Triangle Institute d/b/a RTI Health Solutions",
                    "status": "RECRUITING",
                    "city": "Research Triangle Park",
                    "state": "North Carolina",
                    "zip": "27709",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Study Contact",
                            "role": "CONTACT",
                            "phone": "800-262-3011"
                        }
                    ],
                    "geoPoint": {
                        "lat": 35.90567,
                        "lon": -78.90497
                    }
                }
            ]
        },
        "referencesModule": {
            "seeAlsoLinks": [
                {
                    "label": "To obtain contact information for a study center near you, click here.",
                    "url": "https://pmiform.com/clinical-trial-info-request?StudyID=BHV3000-403"
                }
            ]
        },
        "ipdSharingStatementModule": {
            "ipdSharing": "NO",
            "description": "Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests."
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000008881",
                    "term": "Migraine Disorders"
                }
            ],
            "ancestors": [
                {
                    "id": "D000051270",
                    "term": "Headache Disorders, Primary"
                },
                {
                    "id": "D000020773",
                    "term": "Headache Disorders"
                },
                {
                    "id": "D000001927",
                    "term": "Brain Diseases"
                },
                {
                    "id": "D000002493",
                    "term": "Central Nervous System Diseases"
                },
                {
                    "id": "D000009422",
                    "term": "Nervous System Diseases"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M11852",
                    "name": "Migraine Disorders",
                    "asFound": "Migraine",
                    "relevance": "HIGH"
                },
                {
                    "id": "M9351",
                    "name": "Headache",
                    "relevance": "LOW"
                },
                {
                    "id": "M22529",
                    "name": "Headache Disorders",
                    "relevance": "LOW"
                },
                {
                    "id": "M26657",
                    "name": "Headache Disorders, Primary",
                    "relevance": "LOW"
                },
                {
                    "id": "M5204",
                    "name": "Brain Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M5742",
                    "name": "Central Nervous System Diseases",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BC10",
                    "name": "Nervous System Diseases"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                },
                {
                    "abbrev": "BC23",
                    "name": "Symptoms and General Pathology"
                }
            ]
        }
    },
    "hasResults": false
}